The successful companies of tomorrow will be those that will go beyond delivering products to delivering real-world solutions and services. Truthfully what could be more appropriate than to improve quality of life, remediate miseries and promote longevity of humankind? The advancements in science mean that targeted, cost-effective treatments are within reach. Effective research, principled practice, responsible policies and mindful conscious can create a better tomorrow.
Established in 2015, NLS-1 Pharma AG (NLS-1) is ‘Connecting Brains’ through their innovative R&D which is centered around patient’s needs that designs affordable, safe and effective therapeutics to safeguard and empower the brain throughout all stages of life. The privately owned, Swiss cutting-edge biotech firm is focused on the development of first-in-class treatments for CNS (Central Nervous System) disorders in general and Attention Deficit Hyperactivity Disorder (ADHD) in particular.
‘We value partnership and Integrity; we are ethical and responsible and show respect and compassion for our patients’
An Overarching Cause
ADHD is one of the most common neurodevelopmental disorders of childhood. It is usually first diagnosed in childhood and often persists into adulthood. Children with ADHD may have trouble paying attention, controlling impulsive behaviors and can be hyperactive. It is normal for children to have trouble focusing and behaving properly. However, children with ADHD do not just grow out of these behaviors. The symptoms continue and can cause difficulty at school, at home, or with friends. A child with ADHD might daydream a lot, forget or lose things a lot, make careless mistakes, and may have difficulty getting along with others.
Though current stimulant treatments are effective at improving the symptoms of ADHD for certain patients, they carry a certain risk of abuse, misuse, dependence and are often associated with an undesirable safety profile. On the other hand, non-stimulant treatments can carry side-effects such as suicidal tendencies, severe liver injury and serious cardiovascular risks. Since this condition often also affects children, it is important to create effective as well as safer alternatives. It is due to this reason why the work of companies like NLS-1 matter.
“I am working in this industry because I feel that I can make a difference and help to improve people’s lives”, says Alex Zwyer.
Balancing Science, Ethics, and Business: Meet Alex Zwyer, CEO of NLS-1 Pharma AG
Alex is a leader of the novel deliberation and a strategic acumen with a track record of producing extra-ordinary results for more than 20 years. He is committed to the highest levels of professional and personal excellence. “My passion is to lead people, to pioneer new ideas while never stop learning and excelling in life”, defines Alex. He manages his time by not squeezing as many tasks as possible into his day but does so by being thoughtful, doing things alternatively or in a more efficient way. His philosophy towards work can be defined by the saying, “work smarter, not harder”. “It’s about simplifying how I work, doing things faster, and relieving stress. Delegation is key”, explains Alex.
Recently Alex single-handedly fundraised 15 mil USD and led the successful execution of - what is currently considered as - the most successful phase 2 clinical trial in the ADHD space. Alex believes that any creative and entrepreneurial personality should be oriented towards results, performance, and excellence.
This does not mean he is immune to business challenges. But his ability to not view challenges as a disadvantage instead of being able to overcome adversity is one of his biggest strengths. “Sometimes when you get disappointed it makes you stronger”, affirms Alex.
Living in the Swiss mountains Alex enjoys his spare time hiking, biking, and skiing and tries to spend as much time as possible with his kids.
Innovating Treatment for ADHD
Mazindol (MZD) is a norepinephrine reuptake inhibitor previously approved by the FDA for the treatment of short-term obesity. Since the CNS (central nervous system) noradrenergic and dopaminergic systems appear to be dysfunctional in ADHD and an open-label trial of mazindol demonstrated efficacy in improving the symptoms of pediatrics with ADHD, NLS-1 seeks to confirm the efficacy, tolerability and safety of mazindol C.R. (controlled release) in the treatment of DSM-V (Diagnostic and Statistical Manual of Mental Disorders) Attention Deficit Disorder in adults and pediatrics. The NLS-1 team in their initial study found MZD to be effective for the treatment of children with ADHD. This was confirmed recently by a well-controlled, multicenter phase II study in adults conducted in the US.
NLS-1’s lead compound MZD – is thus very promising and could potentially pave the way for a significant change in how ADHD is treated. “At NLS-1 Pharma I have the privilege of work with some of the best experts for Attention Deficit Hyperactivity Disorder (ADHD) on this planet”, says Alex congratulating his team.
In his plans for a healthy tomorrow, Alex has set the goal to ring the market bell at NASDAQ and buzz in a new area for patients suffering from ADHD worldwide. “My goal is to develop a game-changing therapy in the ADHD space within the next 4 years”, concluded Alex. He might just change the future...
“My goal is to develop a game-changing therapy in the ADHD space within the next 4 years”